In our three cell models, as expected, PCSK9 and HMGCR but not SREBP2 were upregulated at the transcriptional level by pravastatin, which also enhanced expression of PCSK9 and of LDLR—except in FH-iHeps—upon activation of SREBP2. Here, PCSK9 is linked to familial hyperaldosteronism.